Literature DB >> 36174596

Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic.

Russell M Nichols1, Carmen Deveau2, Himanshu Upadhyaya2.   

Abstract

Entities:  

Year:  2022        PMID： 36174596      PMCID： PMC9512274          DOI： 10.1016/S1473-3099(22)00592-8

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   71.421


× No keyword cloud information.
  2 in total

1.  A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab.

Authors:  Maxime Hentzien; Brigitte Autran; Lionel Piroth; Yazdan Yazdanpanah; Alexandra Calmy
Journal:  Lancet Infect Dis       Date:  2022-07-18       Impact factor: 71.421

Review 2.  Neutralizing monoclonal antibodies for treatment of COVID-19.

Authors:  Peter C Taylor; Andrew C Adams; Matthew M Hufford; Inmaculada de la Torre; Kevin Winthrop; Robert L Gottlieb
Journal:  Nat Rev Immunol       Date:  2021-04-19       Impact factor: 108.555
  2 in total
  1 in total

1.  WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed.

Authors:  Mary Y Wu; Edward J Carr; Ruth Harvey; Harriet V Mears; Svend Kjaer; Hermaleigh Townsley; Agnieszka Hobbs; Martina Ragno; Lou S Herman; Lorin Adams; Steve Gamblin; Michael Howell; Rupert Beale; Michael Brown; Bryan Williams; Sonia Gandhi; Charles Swanton; Emma C Wall; David L V Bauer
Journal:  Lancet       Date:  2022-10-06       Impact factor: 202.731
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.